In addition, the downstream targets of the PD-1/PD-L1 pathway (such as SHP2 and PTEN agonists, PI3K/AKT/mTOR inhibitors, etc.)may also be potential therapeutic targets for MS. This evidence concerns the gene CD274 and myeloid sarcoma.